Cyclosporine A (CsA) therapy based on 2-h concentrations (C2) after oral administration has demonstrated low acute rejection rates after solid organ transplantation. We analysed the correlation between C2 and trough (C0) levels of oral CsA therapy in samples obtained twice in consecutive weeks from 58 patients during their first admission for allogeneic haematopoietic stem cell transplantation. Also 8-h concentration curves were obtained from 23 patients. The mean (range) CsA dose was 332 (167-763) and 255 (113-575) mg/day for patients with matched unrelated donor (MUD) and human leukocyte antigen identical sibling donor (Sib), respectively. Median (range) C0 and C2 were 254 (145-332) and 898 (419-1466) ng/ml in MUD patients, and 130 (93-265) and 554 (196-988) ng/ml in Sib patients. In MUD patients with either aGVHD grade oII or XII, the median C2 were 915 (419-1466) and 890 (519-1399) ng/ ml, respectively. In Sib patients with aGVHD grade oII or grade XII, the median C2 were 552 (404-718) and 539 (196-988) ng/ml, respectively. The median C2 levels were comparable in patients with or without severe infections. Interindividual variations in CsA uptake and metabolism may explain the wide variation of C2 levels without prediction for increased risk for severe aGVHD or infectious complication when C0 guided the CsA dosing.
Introduction
Cyclosporine A (CsA) is the most common prophylactic immunosuppressive drug against graft-versus-host disease (GVHD) and organ transplant rejection. Over the years, as CsA has been used for the prevention of organ transplant rejection, a relationship has been shown between CsA blood levels and clinical outcome measured by toxicity and the rate of rejection. 1, 2 Several different strategies for monitoring CsA concentrations have been suggested, based on different pharmacokinetic and pharmacodynamic assumptions. Traditionally, sampling is performed before drug intake in the morning, approximately 12 h after the last dose (in a twicedaily dosage scheme). This trough, or lowest concentration value (C0), during the dose interval has some advantages. First, it is practical and not so sensitive as to the exact timing of the sampling. Second, it has been well documented throughout the years. A trough value is also likely to expose recent poor compliance in an out-patient setting. As for drawbacks, it has been argued that the trough concentration relates poorly to the area under the curve concentration (AUC), and that the maximal pharmacodynamic response to CsA, as measured by inhibition of calcineurin activity, coincides with the concentration peak approximately at 2 h after dose intake. 3 Thus, concentration sampling 2 h after dose intake (C2) has been suggested as a better measure of both total drug exposure and effect in kidney, heart and liver transplant patients. [4] [5] [6] [7] In other series of liver and heart transplant patients, no clinical superiority (lower incidence of acute graft rejections) was demonstrated using C2 levels. 8, 9 A definite drawback of C2 measures is that they are sensitive to minor deviations in sampling time. Also, many of the studies of C2 levels have been performed in patients initially monitored by their C0, meaning that a change to C2 monitoring adds pharmacokinetic information, and cannot be seen as independent of earlier interventions. In solid organ transplantation, the current practice of monitoring, by C0 or C2 or both, varies between centres. There seems to be a consensus that in the early posttransplant period, and in patients with poor or erratic drug absorption, additional C2 sampling is valuable to support the individual dosing.
C2 monitoring of oral CsA microemulsion therapy has not been investigated previously in haematopoietic stem cell transplantation (HSCT) patients. Obtained and/or optimal C2 concentrations must not necessarily equal those achieved or targeted in solid organ transplantation. First, drug absorption may be influenced by intestinal motility and the status of the intestinal mucosa, which in HSCT may be altered, for example, by preparative regimens with chemotherapy and/or irradiation, the hydration status of the patient, as well as the possible presence of acute GVHD (aGVHD). Second, in HSCT, but not in solid organ transplantation, the use of immunosuppressive treatment may allow for a continuous, mild immune activity associated with graft-versus-leukaemia or graft-versus-tumour effect.
The primary aim of the present study was to analyse C2 and C0 levels in HSCT patients with either matched unrelated donors (MUD) or human leukocyte antigen (HLA) identical sibling donors (Sib), their inter-and intraindividual variation, and the correlation between C2, C0 and the AUC of CsA. The secondary aim was to analyse the incidence of aGVHD and severe infections of microemulsified CsA in relation to C2 and C0 levels.
Materials and methods

Patients and donors
Fifty-eight patients treated with allogeneic HSCT at the Karolinska University Hospital Huddinge in Stockholm between January 2002 and June 2004 were monitored biweekly for C0 of CsA in peripheral blood samples obtained during the first admission of HSCT. At least one additional C2 sample was also prospectively collected from all patients. In 23 patients, sampling for a full 12-h AUC was performed. The incidences of infectious complications and GVHD during 3 months post transplant were registered. The study group consisted of 20 women and 38 men, with a median age of 43.7 (range 8.7-64.0) years. There were eight children o18 years. The majority of patients (n ¼ 34) were transplanted for acute or chronic leukaemia, lymphoma or myeloma. Eleven patients had metastatic solid cancer. A more detailed patient demography is presented in Table 1 .
Patients and donors were HLA typed with a highresolution PCR single-stranded primSSP method for HLA class I and II. 12 All donors were at least HLA-A, -B and DRb1 compatible with the recipient. An HLA-identical sibling donor (n ¼ 16) was given priority but, if not available, an HLA MUD (n ¼ 42) was used ( Table 1) . From all donors, peripheral blood stem cells were collected after stimulation with granulocyte-colony stimulating factor (Neupogen, Amgen, Stockholm, Sweden). 13 All patients gave their informed consent to participate in the study, which was approved by the local medical ethics committee and performed in accordance with the Declaration of Helsinki guidelines for good clinical practice.
Conditioning, GVHD prophylaxis and treatment
Conditioning was totally myeloablative in 47 patients (Table 1 ). Cyclophosphamide at 120 mg/kg was administered for 2 days, combined with total-body irradiation or busulfan at 16 mg/kg for 4 days.
14 In 11 solid tumour patients, reduced-intensity conditioning was given using cyclophosphamide at 30 mg/kg BW/day for 2 days together with fludarabine at 30 mg/m 2 for 3 or 5 days in patients with Sib or MUD, respectively.
15 Antithymoglobulin (Thymoglobuline, Genzyme, Cambridge, MA, USA) was administered at 4-8 mg/kg depending on the disease type to all patients with MUD (n ¼ 42; Table 1 ). 16 All patients with myeloablative conditioning received initially CsA (Sandimmun, Novartis Pharma AG, Stein, Switzerland) 0.5 or 2.5 mg/kg intravenous (i.v.) twice daily if receiving the graft from Sib or MUD, respectively. The following oral dosing of microemulsified CsA (Sandimmun Neoral, Novartis Pharma AG, Stein, Switzerland) was started on day þ 1 after SCT at 1.5 or 6.25 mg/kg twice daily if the donor was Sib or MUD, respectively. The patients with reduced conditioning received oral CsA of 5 mg/kg twice daily from day -2 before HSCT. Further dose adjustments were based on biweekly C0 measurements to achieve C0 of 100 ng/ml and 250-300 ng/ml during the first month after HSCT in patients with Sib and MUD, respectively. Tapering of CsA was started 1 month after HSCT and discontinued at 3-6 months in the absence of GVHD.
Adjunctive prophylactic therapy against GVHD consisted of four doses of methotrexate (n ¼ 52) given once as 15 mg/m 2 i.v. and followed by 10 mg/m 2 as described earlier. 17, 18 The remaining patients were given mycophenolate mofetil (Cellcept, Hoffman LaRoche, Basel, Switzerland), (n ¼ 3) or steroids (n ¼ 3). [19] [20] [21] aGVHD grade I was treated with i.v. prednisolone (1 mg/kg b.d.). Additional therapeutic strategies against The additional supportive therapy has been described earlier. 14, [16] [17] Cyclosporine A concentration measurements The whole-blood C0 and C2 were analysed in peripheral blood samples obtained from fasted patients before and 2 h after oral intake of the morning doses in connection to the breakfast, respectively. The CsA concentration was analysed using the Cedia Cyclosporine PLUS assay (Microgenics Corp., Fremont, CA, USA), with an inter-run coefficient of variation of 5.2% at 100 ng/ml and 2.4% at 1200 ng/ml, and an intrarun variation of 5.0 and 2.2%, respectively. The lower limit of detection was 25 ng/ml, and only runs with less than 15% deviation from the controls were approved.
Repeated samples at 0, 1, 1.5, 2, 3, 5 and 8 h after CsA administration, were obtained for determination of the linear trapezoidal AUC (0-8 h) in 23 patients. AUC (0-12 h) for the whole dosage interval was extrapolated based on the slope of the 3-8 h samples.
Definitions aGVHD was diagnosed from clinical findings and/or biopsies from skin, oral mucosa or liver. It was graded from I to IV according to defined criteria. 23 Chronic 24 It is graded as limited or extensive.
Cytomegalovirus (CMV) infection and disease were defined according to previously published criteria. 25 For herpes simplex and varicella zoster virus infection, virus isolation from affected tissue was needed. Bacteriaemia required positive blood culture related to a febrile episode (X38.51C). Invasive fungal infection was defined as positive blood culture and/or positive cultures from at least two organs for Candida or Aspergillus species. Aspergillus pneumonia was defined as pulmonary infiltrates and positive cultures or direct microscopy of bronchoalveolar lavage fluid, sputum or autopsy specimens.
Statistics
The two-tailed Fischer's exact test was used for the analysis of categorical data. The Mann -Whitney U-test was used for comparing continuous variables. A P-value o0.05 was chosen to show a statistically significant difference. No power analysis was performed in relation to clinical outcome data, as this was not the primary aim of the study.
Results
The total number of samples for C2 analyses was 248, with a mean of 4.3 (range 1-10) samples per patient during the first admission for HSCT. Approximately half of the patients had the first sample for C2 levels obtained during the second week after HSCT when on stable oral nutrition.
The mean (range) oral doses of CsA administered were 338 (167-763) and 234 (113-400) mg/day for patients with MUD and Sib, respectively. Mean (range) C0 and C2 were 255 (128-332) and 895 (419-1466) ng/ml, respectively in MUD patients, and 143 (93-265) and 541 (196-988) ng/ml, respectively in Sib patients (Figures 1a and b) .
Thus, mean C2/C0 ratios were 3.3 (1.8-6.5) and 3.6 (1.0-6.1) for patients with MUD and Sib, respectively (not significant (NS)). The correlation coefficient for the C2-C0 relation was 0.48 (Po0.001) in MUD and 0.49 (Po0.001) in Sib (Figure 2) . When comparing adults (n ¼ 37) and children (n ¼ 6) within the MUD group, the children had a higher mean C2/ C0 ratio of 4.7, versus 3.1 in the adults (Po0.01), as could be expected from the known higher clearance in children.
The mean C0/dose was 0.78 ng/ml/mg in the MUD group and 0.57 ng/ml/mg in the Sib group (Po0.05), whereas the mean C2/dose did not differ significantly (2.56 and 2.28 ng/ml/mg, respectively).
The mean AUC (0-12 h) was 4667 (1216-7021) ng/ml*h in MUD patients (n ¼ 13) and 3003 (710-4437) ng/ml*h in Sib patients (n ¼ 10). All the individual concentration curves from 0 to 8 h are shown in Figure 3 . The maximal concentration was detected at a mean (range) of 1.8 (1.0-3.0) h after dose intake in both patient groups. AUC correlated relatively well with both C0 (r ¼ 0.77) and C2 (r ¼ 0.86).
The incidence of aGVHD gradeXII was 26% (11/42) and 50% (8/16) in patients with MUD and Sib, respectively (NS). The median (range) C2 was 620 (196-1399) and 798 (404-1466) mg/ml in patients with aGVHD gradeXII and those with aGVHD grade oII, respectively (NS). In patients grafted with Sib and who developed aGVHD gradeoII or gradeXII, the median C2 were 552 (404-718) and 539 (196-988) ng/ml, respectively (NS; Figure 4a ). In patients grafted with MUD and who were diagnosed with aGVHD grade oII or gradeXII, the median C2 was 915 (419-1466) and 890 (519-1399) ng/ml, respectively (NS; Figure 4b ).
The incidence of severe bacterial and viral infections was 40% (23/58) and 24% (14/58), respectively. The most common bacterial infections occurred median 10 (range, 1-80) days after HSCT, and were due to Gram-positive bacteria (Table 2) . Severe viral infections were most often due to varicella zoster virus and CMV disease. In patients with severe bacterial infection, with viral infection and in those without these infections, the median (range) C2 levels were 798 (419-1466), 851 (331-1341) and 789 (404-1222) ng/ml, respectively. 
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The patients with MUD and suffering from severe bacterial infection had lower median C2 compared with those without bacterial infection: 798 (419-1466) versus 1003 (549-1334) ng/ml (P ¼ 0.05). The opposite was found in patients with Sib and bacterial septicaemia. There were no differences in median C2 and C0 concentrations in patients with MUD or Sib and suffering from severe virus infections as compared with those without severe virus infection (data not shown).
Discussion
As judged by the CsA concentration curves from the 23 patients in the present study, a sample taken 2 h after dose intake does well mirror the maximal concentration in HSCT patients, irrespective of the HLA matching. Achieved C2 concentrations, as expressed by an approximation of the interquartile range in the present study were between 450 and 600 ng/ml and between 700 and 1000 ng/ ml for patients transplanted with Sib and MUD, respectively. The incidence of aGVHD in Sib patients was higher than previously reported, whereas the incidence of aGVHD in MUD patients, as well as the incidences of severe bacterial and viral infections in the whole study group, were in line with what has been reported by our centre and by others in larger HSCT cohorts. 13, 26, 27 Different C2 target concentrations have been suggested in different solid organ transplantation settings, varying between 1400 and 1600 ng/ ml early after renal transplantation to 400 and 600 ng/ml in 2-h cyclosporine A concentration L Barkholt et al stable liver transplant recipients. 11 The C2 ranges found in the present study must not necessarily represent ideal values, but can probably be used as guidance of CsA dosing in some patients, as a complement to trough measures for example when using concomitant drugs that may cause pharmacokinetic interactions. A previously published study on HSCT patients, comparing C2 values after continuous and 2-h infusion of 1.5 mg/kg twice daily of CsA, reported CsA concentrations between 659 and approximately 1400 ng/ml at the end of 2-h infusions. 28 The authors recommend intravenous CsA dosing to reach C24800 ng/ ml in HSCT patients, based on the theoretical reasoning concerning calcineurin inhibition. This recommendation cannot be said to be supported by their study data, as they have not investigated the clinical outcome at different C2 levels.
Compared with data from studies in for example heart transplant recipients, dose-related C2 seems to be lower in our HSCT patients (191 and 160 ng/ml/mg/kg), which can probably be related to poorer absorption, as discussed above. Cantarovich et al. 4 reported a mean C2/dose of 278 ng/ml/mg/kg and Caforio et al. 7 a mean of 250 ng/ml/ mg/kg. In patients with sibling donors, the median C0 during the first month after transplantation was found to be considerably higher (141 ng/ml) than the aim (100 ng/ ml), whereas in patients with MUD, the median C0 of 274 ng/ml was within the desired range of 250-300 ng/ml. Somewhat surprisingly, the C0/dose was higher in the first group, whereas C2/dose did not differ significantly. If not a random finding, this could indicate lower CsA clearance in the MUD group, which could possibly be related to the more intense conditioning before MUD transplantation, as shown by a dominance of inflammatory cytokines during and early after the preparative regimen. 29 Other, in parallel with CsA, administered drugs were similar in patients with MUD and Sib.
In the present material, we could see no correlation between C2 concentrations and either aGVHD or the occurrence of infections. This may be due to a true lack of correlation or to any (or many) of several sources of error in the present study. First, the study was not powered to enable analysis of anything but very prominent effects. Second, as this is an observational study, and did not involve any form of randomization to either doses or concentration levels, there may be several confounders between achieved drug concentrations and clinical outcome. For example, a trend towards lower C2 concentrations in patients with MUD that had severe bacterial infections could possibly be explained by affected intestinal mucosa as a common etiology and/or lower dosing. Also, C2 concentrations in patients with aGVHD of intestine (grade III-IV) may have been confounded by poor absorption. It could, however, indicate that the C2 levels reached in this group, with a median of 539 ng/ml, were suboptimal. Furthermore, dosage decisions are based both on concentrations achieved and on the clinical condition of the patient, for example severe infection or renal impairment would lead the physician to decrease the CsA dose and vice versa if a patient suffered from aGVHD.
In conclusion, C2 concentrations attained were lower in stem cell transplant patients compared with what has been reported in solid organ transplantation. We found no correlation between C2 and either severe aGVHD or infection in this HSCT group of patients with C0-guided CsA dosing. Randomized, concentration-controlled studies and population kinetic studies in larger patient groups would be needed to further describe the association between CsA concentrations and its' effect, with an aim to individualize the treatment better by avoiding toxicity and suboptimal immunosuppressive treatment. 2-h cyclosporine A concentration L Barkholt et al
